Physician profile
Jeffrey Johnson
NPI 1275647117
$648.08
in general payments reported to CMS, 2019-2025
14 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.79 · 2020: $58.23 · 2021: $73.82 · 2022: $106 · 2023: $15.62 · 2024: $131 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $144.50 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Glaxosmithkline, LLC. | $61.36 | 2019-2023 | Arexvy, Shingrix, Boostrix |
| Lilly USA, LLC | $61.20 | 2021-2022 | |
| Insmed, INC. | $58.12 | 2021-2024 | Arikayce |
| Viiv Healthcare Company | $54.42 | 2025 | Dovato, Apretude |
| Shionogi INC | $42.81 | 2025 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $42.05 | 2020-2021 | |
| Abbvie INC. | $38.11 | 2024 | |
| Paratek Pharmaceuticals, INC. | $38.00 | 2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $36.52 | 2025 | Xacduro, Zevtera |
| Theratechnologies INC. | $22.48 | 2022 | |
| Gilead Sciences, INC. | $18.54 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.60 | 2022 | |
| Allergan, INC. | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.